真实临床环境下接受胸部放疗的小细胞肺癌患者总生存、无进展生存及毒性相关因素分析
该回顾性研究分析了57例局限期和69例广泛期小细胞肺癌患者接受胸部放疗的预后因素,发现较晚开始放疗(化疗3周期后)与局限期和广泛期患者总生存及无进展生存改善相关,KPS≥80与广泛期患者生存改善相关,女性和较低平均肺剂量与局限期患者毒性风险降低相关。
要点
- 局限期患者早期、晚期、极晚期开始放疗的中位OS分别为23.7、22.0个月及未达到,PFS分别为11.8、15.2、47.9个月。
- 广泛期患者早期、晚期、极晚期开始放疗的中位OS分别为4.3、13.0、12.2个月,PFS分别为6.7、13.0、12.2个月。
- 局限期和广泛期患者晚期或极晚期开始放疗较早期开始,OS和PFS显著延长(p<0.05)。
核心结论
- 晚期或极晚期开始放疗是局限期和广泛期小细胞肺癌患者OS和PFS的预后增强因素。
- KPS≥80可改善广泛期小细胞肺癌患者的OS和PFS预后。
- 女性和较低平均肺剂量与局限期小细胞肺癌患者毒性风险降低相关。
研究设计与样本
- 回顾性分析57例局限期和69例广泛期小细胞肺癌接受胸部放疗的患者。
- 评估性别、年龄、KPS、肿瘤分期、淋巴结分期及放疗开始时间(相对化疗第一周期)等预后因素。
- 放疗开始时间分为早期(≤2周期化疗)、晚期(3或4周期)和极晚期(≥5周期)。
- 采用Cox单因素和多因素分析以及逻辑回归分析。
主要发现
- 局限期患者早期、晚期、极晚期开始放疗的中位OS分别为23.7、22.0个月及未达到,中位PFS分别为11.8、15.2、47.9个月。
- 广泛期患者早期、晚期、极晚期开始放疗的中位OS分别为4.3、13.0、12.2个月,中位PFS分别为6.7、13.0、12.2个月。
- 局限期或广泛期患者晚期或极晚期开始放疗较早期开始,OS和PFS显著延长(p<0.05)。
- 广泛期患者KPS≥80与OS和PFS显著增加相关。
- 女性和较低平均肺剂量与局限期患者毒性风险降低相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small-cell lung cancer (SCLC) is a malignant tumor known for its poor prognosis. In addition to chemotherapy and immunotherapy irradiation plays a big role especially in inoperability. This study evaluated prognostic factors in patients with SCLC, receiving chemotherapy and thoracic irradiation, that may affect overall survival (OS), progression-free survival (PFS) and toxicity. METHODS: Patients with limited disease (LD) SCLC (n = 57) and extensive disease (ED) SCLC (n = 69) who received thoracic radiotherapy were analyzed retrospectively. The prognostic factors sex, age, Karnofsky performance status (KPS), tumor-, nodal-stage and timepoint of start of irradiation in relation to the first cycle of chemotherapy were evaluated. Start of irradiation was stratified as early ([Formula: see text] 2 cycles of chemotherapy), late (3 or 4 cycles) and very late ([Formula: see text] 5 cycles). Results were analyzed by Cox univariate and multivariate as well as logistic regression analysis. RESULTS: The median OS of LD-SCLC patients was 23.7 months in early, and 22.0 months in late start of irradiation. In very late start, median OS was not reached. PFS was 11.8, 15.2 and 47.9 months, respectively. In patients with ED-SCLC OS was 4.3 months in early, 13.0 months in late and 12.2 months in very late start of irradiation. PFS was 6.7, 13.0 and 12.2 months, respectively. Prognosis of patients with LD- or ED-SCLC receiving late or very late start of irradiation was significantly prolonged in OS and PFS compared to an early start (p < 0.05). KPS [Formula: see text] 80 shows a significant increase of OS and PFS in ED-SCLC. Female sex and smaller mean lung dose were associated with lower risk of toxicity. CONCLUSION: Late or very late start of irradiation is a prognosis-enhancing factor in LD-SCLC and ED-SCLC for OS and PFS. KPS [Formula: see text] 80 increases prognosis of OS and PFS in ED-SCLC as well. Toxicity is less common in female sex and patients with low mean lung dose in LD-SCLC.
引用
- Kassik MT, Vordermark D, Kornhuber C, et al. Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting. Radiat Oncol. 2023. PMID: 37072833. doi:10.1186/s13014-023-02252-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。